TY - JOUR
T1 - The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes
AU - Berger, William E.
AU - Legorreta, Antonio P.
AU - Blaiss, Michael S.
AU - Schneider, Eric C.
AU - Luskin, Allan T.
AU - Stempel, David A.
AU - Suissa, Samy
AU - Goodman, David C.
AU - Stoloff, Stuart W.
AU - Chapman, Jean A.
AU - Sullivan, Sean D.
AU - Vollmer, Bill
AU - Weiss, Kevin B.
N1 - Funding Information:
¶¶ Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, Washington. ‖‖ Kaiser Permanente Center for Health Research, Portland, Oregon. *** Midwest Center for Health Services and Policy Research, Hines VA Hospital, and Center for Healthcare Studies and Division of General Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. This study was supported in part by GlaxoSmithKline. Received for publication May 3, 2004. Accepted for publication in revised form June 10, 2004.
PY - 2004/12
Y1 - 2004/12
N2 - Background: The Health Plan Employer Data and Information Set (HEDIS) measures are used extensively to measure quality of care. Objective: To evaluate selected aspects of the HEDIS measure of appropriate use of asthma medications. Methods: Claims data were analyzed for commercial health plan members who met HEDIS criteria for persistent asthma in 1999. The use of asthma medications was evaluated in the subsequent year with stratification by controller medication and a measure of adherence (days' supply). Multivariate logistic regressions were used to evaluate the association among long-term controller therapy for persistent asthma, adherence to therapy, and asthma-related hospitalizations or emergency department (ED) visits, controlling for demographic, preindex utilization, and other confounding characteristics. Results: Of the 49,637 persistent asthma patients, approximately 35.7% were using 1 class of long-term controller medications, 18.4% were using more than 1 class, and 45.9% were not using such medication. More than 25% of the persistent asthma patients did not use any asthma medication in the subsequent year. Patients with low adherence to controller medication had a significantly higher risk (odds ratio [OR], 1.72; 95% confidence interval [CI], 1.42-2.08) of ED visit or hospitalization relative to patients not using any controllers compared with persons with moderate (OR, 0.84; 95% CI, 0.57-1.23) or high (OR, 0.70; 95% CI, 0.34-1.44) adherence. Patients receiving a high days' supply of inhaled corticosteroids had the lowest risk of ED visit or hospitalization (OR, 0.37; 95% CI, 0.05-2.69). Conclusions: Our findings suggest that refinements to the HEDIS measure method for identifying patients with persistent asthma may be needed.
AB - Background: The Health Plan Employer Data and Information Set (HEDIS) measures are used extensively to measure quality of care. Objective: To evaluate selected aspects of the HEDIS measure of appropriate use of asthma medications. Methods: Claims data were analyzed for commercial health plan members who met HEDIS criteria for persistent asthma in 1999. The use of asthma medications was evaluated in the subsequent year with stratification by controller medication and a measure of adherence (days' supply). Multivariate logistic regressions were used to evaluate the association among long-term controller therapy for persistent asthma, adherence to therapy, and asthma-related hospitalizations or emergency department (ED) visits, controlling for demographic, preindex utilization, and other confounding characteristics. Results: Of the 49,637 persistent asthma patients, approximately 35.7% were using 1 class of long-term controller medications, 18.4% were using more than 1 class, and 45.9% were not using such medication. More than 25% of the persistent asthma patients did not use any asthma medication in the subsequent year. Patients with low adherence to controller medication had a significantly higher risk (odds ratio [OR], 1.72; 95% confidence interval [CI], 1.42-2.08) of ED visit or hospitalization relative to patients not using any controllers compared with persons with moderate (OR, 0.84; 95% CI, 0.57-1.23) or high (OR, 0.70; 95% CI, 0.34-1.44) adherence. Patients receiving a high days' supply of inhaled corticosteroids had the lowest risk of ED visit or hospitalization (OR, 0.37; 95% CI, 0.05-2.69). Conclusions: Our findings suggest that refinements to the HEDIS measure method for identifying patients with persistent asthma may be needed.
UR - http://www.scopus.com/inward/record.url?scp=10344236008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10344236008&partnerID=8YFLogxK
U2 - 10.1016/S1081-1206(10)61260-4
DO - 10.1016/S1081-1206(10)61260-4
M3 - Article
C2 - 15609762
AN - SCOPUS:10344236008
SN - 1081-1206
VL - 93
SP - 538
EP - 545
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 6
ER -